Comparing neutrophil-to-lymphocyte ratio (NLR), absolute neutrophil count (ANC) and derived NLR as predictive biomarkers in first-line immunotherapy for non-small cell lung cancer: a retrospective study.

Date publication

avril 2025

Journal

Translational lung cancer research

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DALSTEIN Véronique , Pr POLETTE Myriam , Dr NAWROCKI-RABY Béatrice

Tous les auteurs :
Longueville E, Dewolf M, Dalstein V, Durlach A, Vivien A, Nawrocki-Raby B, Polette M, Deslée G, Ancel J

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40386737

Résumé

Lung cancer, especially non-small cell lung cancer (NSCLC), poses a significant global health challenge due to its high prevalence and poor prognosis despite treatment advancements, including immunotherapy. While programmed death-ligand 1 (PD-L1) expression is a commonly used biomarker, its limitations justify exploration of alternative markers like the neutrophil-to-lymphocyte ratio (NLR), absolute neutrophil count (ANC) and derived NLR (dNLR). This retrospective study aims to directly compare NLR, ANC and dNLR as predictive biomarkers in first-line NSCLC immunotherapy, shedding light on their prognostic implications and potential clinical utility.

Mots clés

Non-small cell lung cancer (NSCLC), biomarker, derived neutrophil-to-lymphocyte ratio (dNLR), immunotherapy, neutrophil-to-lymphocyte ratio (NLR)

Référence

Transl Lung Cancer Res. 2025 04 30;14(4):1212-1230